The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients

Acta Neurologica Scandinavica

Volumn 111, Issue 2, 2005, Pages 89-94

  Stryjer, R ^a   Klein, C ^a   Treves, T A ^b   Rabey, J M ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Norepinephrine; Orthostatic test; Parkinson's disease; Postural hypotension; Rasagiline; Selegiline

Indexed keywords

LEVODOPA; NORADRENALIN; SELEGILINE;

ACUTE DRUG ADMINISTRATION; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FUNCTION TEST; HUMAN; LOADING TEST; LOGISTIC REGRESSION ANALYSIS; MALE; NORADRENALIN BLOOD LEVEL; ORTHOSTATIC HYPOTENSION; ORTHOSTATIC TEST; PARKINSON DISEASE; PULSE RATE; SIDE EFFECT; STANDING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VOLUNTEER;

AGED; ANTIPARKINSON AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NOREPINEPHRINE; PARKINSON DISEASE; PULSE; REST; SELEGILINE; SUPINE POSITION;

EID: 12944301006     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00294.x     Document Type: Article

References (27)

1. BIRKMAYER W, RIEDERER P, AMBROZI L et al. Implications of combined treatment with "Madopar" and L-deprenyl in Parkinson's disease. Lancet 1977;1:439-43.
2. RINNE UK. Combination of a dopamine agonist, MAO-B inhibitor and levodopa - a new strategy in the treatment of early Parkinson's disease. Acta Neurol Scand 1989;126:165-9.
3. STREIFLER M, VARDI J, BORENSTEIN N, RABEY JM, FLECHTER S. B-type Monoamine oxidase (M.A.O.) inhibitors in long-term levodopa treated Parkinsonism. A combined clinical trial with L-deprenyl. Curr Ther Res Clin Exp 1980;27:643-8.
4. BIRKMAYER W, KNOLL J, RIEDERER P et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long term study. J Neural Transm 1985;64:113-27.
5. LEES AJ, on behalf of the Parkinsonian's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-7.
6. OLANOW CW, MYLLYLA VV, SOTANIEMI KA et al. Effects of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998;51:825-30.
7. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996;46:1471-1480.
8. MARTIGNONI E, MICIELI G, CAVALLINI A, PACCHETTI C, MAGRI M, NAPPI G. Autonomic disorders in idiopathic parkinsonism. J Neural Transm Suppl 1986;22:149-61.
9. PIHA SJ, RINNE JO, RINNE UK, SEPPANEN A. Autonomic dysfunction in recent onset and advanced Parkinson's disease. Clin Neurol Neurosurg 1988;90:221-6.
10. SENARD JM, RAI S, LAPEYRE-MESTRE M et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-9.
11. HAINSWORTH R. Syncope and fainting. In: Bannister B, Mathias CJ, eds. Autonomic failure. A textbook of the autonomic nervous system, 3rd edn. Oxford: OUP, 1992;210-15.
12. CHURCHYARD A, MATHIAS CJ, PHIL D, LEES AL. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effect of drug withdrawal. Mov Dis 1999;14:246-51.
13. REYNOLD GP, ELSWORTH JD, BLAU K et al. Deprenyl is metabolized to metamphetamine and amphetamine in man. Br J Clin Pharmacol 1978;6:542-4.
14. GILL JR, MASON DT, BARTTER FC. Effects of hydroxyamphetamine (paredrine) on the function of the sympathetic nervous system in normotensive subjects. J Pharmacol Exp Ther 1967;155:288-95.
15. CAVANAUGH JH, GRITH JD, OATES JA. Effects of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man. Clin Pharmacol Ther 1970;11:656-64.
16. LOW PA, POLINSKY RJ, KAUFMANN HC et al. Autonomic function and dysfunction. Part A Continuum. Lifelong Learn Neurol 1998;4:14-5.
17. MINATOGUCHI S, ITO H, ISHIMURA K et al. Plasma adrenaline modulates alpha 1-adrenoreceptor mediated pressor responses and the baroreflex control in patients with borderline hypertension. Blood Press 1995;4:105-12.
18. RANGNO RE, KAUFMANN JS, CAVANAUGH JH et al. Effects of a false neurotransmitter, p-hydroxynorephedrine, on the function of adrenergic neurons in hypertensive patients. J Clin Invest 1973;52:952-60.
19. WALDMEIER PC, FELNER AE. Deprenyl: loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 1978;27:801-2.
20. EKSTEDT B, MAGYAR K, KNOLL J. Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? Biochem Pharmacol 1979;28:919-23.
21. MCDANIEL KD. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol 1986;9:207-34.
22. RIEDERER P, YOUDIM MBH, RAUSCH WD et al. On the mode of action of L-deprenyl in the human nervous system. J Neural Transm 1978;43:17-26.
23. CHURCHYARD A, MATHIAS CJ, BOONKONGCHUEN P et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:228-34.
24. NIEHAUS L, BÖCKELER GC, KUPSCH A, MEYER BU. Normal cerebral hemodynamic response to orthostasis in Parkinson's disease. Parkinsonism Relat Disord 2003;8:255-60.
25. Parkinson's Study Group. A controlled trial of rasagiline in early Parkinson's Disease. Ann Neurol 2000;48:489.
26. RABEY JM, SAGI I, HUBERMAN M et al. Rasagiline mesylate, a new Mao-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000;23:324-30.
27. BLINDAUER K, for the Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO Study). Neurology 2001;56:A345.